|
|
|
|
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
-Subunit of the Eukaryotic Initiation Factor Kinase?
Departments of Cellular and Molecular Pharmacology (X.-M.H., M.A.C.), Pharmaceutical Chemistry (M.A.C.), Biopharmaceutical Sciences (M.A.C.), and Medicine (G.L., C.H., J.J.M.), and The Liver Center (X.-M.H., M.A.C., G.L., C.H., J.J.M.), University of California, San Francisco, California
The role of heme in the phenobarbital-mediated induction of CYP2B1/2 was reexamined in rat hepatocytes in monolayer culture, acutely depleted of heme by treatment with either 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine (DDEP) or N-methylprotoporphyrins (NMPP). The findings revealed that such acute hepatic heme depletion markedly impaired CYP2B1/2 protein induction, an effect that was reversible by heme resupplementation. However, TaqMan analyses of hepatic mRNA isolated from these heme-depleted cells revealed that this impairment was not due to faulty transcriptional activation of either CYP2B1 or CYP2B2 gene expression as previously proposed, thereby confirming literature reports that heme is not a transcriptional regulator of the CYP2B1/2 gene. In contrast, the rate of de novo CYP2B1/2 protein synthesis was found to be dramatically inhibited in both DDEP- and NMPP-treated hepatocytes. Concurrently, a marked (>80%) suppression of de novo hepatocellular protein synthesis was also observed, along with a significantly enhanced phosphorylation of the
-subunit of the eukaryotic initiation factor eIF2 (eIF2
), as monitored by the phosphorylated eIF2
/total eIF2
ratio in these heme-depleted cells. Indeed, the parallel reversal of all these three effects by heme supplementation suggests that this impaired CYP2B1 induction most likely stems from blocked translational initiation resulting from the activation of a heme-sensitive eIF2
kinase. Such global suppression of hepatic protein synthesis may disrupt a myriad of vital cellular functions, thereby contributing to the clinical symptoms of acute hepatic heme-deficient states such as the hepatic porphyrias.
Address correspondence to: Dr. M. A. Correia, Department of Cellular and Molecular Pharmacology, Box 0450, University of California, San Francisco, CA 94143-0450. E-mail: mariac{at}itsa.ucsf.edu
This article has been cited by other articles:
![]() |
P. Acharya, J. C. Engel, and M. A. Correia Hepatic CYP3A Suppression by High Concentrations of Proteasomal Inhibitors: A Consequence of Endoplasmic Reticulum (ER) Stress Induction, Activation of RNA-Dependent Protein Kinase-Like ER-Bound Eukaryotic Initiation Factor 2{alpha} (eIF2{alpha})-Kinase (PERK) and General Control Nonderepressible-2 eIF2{alpha} Kinase (GCN2), and Global Translational Shutoff Mol. Pharmacol., September 1, 2009; 76(3): 503 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Igarashi, M. Murase, A. Iizuka, F. Pichierri, M. Martinkova, and T. Shimizu Elucidation of the Heme Binding Site of Heme-regulated Eukaryotic Initiation Factor 2{alpha} Kinase and the Role of the Regulatory Motif in Heme Sensing by Spectroscopic and Catalytic Studies of Mutant Proteins J. Biol. Chem., July 4, 2008; 283(27): 18782 - 18791. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liao, M. K. Pabarcus, Y. Wang, C. Hefner, D. A. Maltby, K. F. Medzihradszky, S. P. Salas-Castillo, J. Yan, J. J. Maher, and M. A. Correia Impaired Dexamethasone-Mediated Induction of Tryptophan 2,3-Dioxygenase in Heme-Deficient Rat Hepatocytes: Translational Control by a Hepatic eIF2{alpha} Kinase, the Heme-Regulated Inhibitor J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 979 - 989. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Abdulla, K. B. Goralski, E. G. Del Busto Cano, and K. W. Renton THE SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN HEPATIC CYTOCHROME P450 REGULATION IN THE RAT DURING A LIPOPOLYSACCHARIDE-INDUCED MODEL OF CENTRAL NERVOUS SYSTEM INFLAMMATION Drug Metab. Dispos., October 1, 2005; 33(10): 1521 - 1531. [Abstract] [Full Text] [PDF] |
||||